Christopher Calise's most recent trade in Coeptis Therapeutics Holdings Inc was a trade of 5,700 Non-qualified Stock Options (right to buy) done . Disclosure was reported to the exchange on March 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Coeptis Therapeutics Holdi... | Christopher Calise | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 5,700 | 8,950 | - | - | Non-qualified Stock Options (right to buy) | |
| Coeptis Therapeutics Holdi... | Christopher Calise | Director | Purchase of securities on an exchange or from another person at price $ 0.94 per share. | 23 Aug 2023 | 9,000 | 1,462,315 | - | 0.9 | 8,460 | Common Stock |
| Coeptis Therapeutics Holdi... | Christopher Calise | Director | Purchase of securities on an exchange or from another person at price $ 0.94 per share. | 23 Aug 2023 | 2,582 | 1,464,897 | - | 0.9 | 2,419 | Common Stock |
| Coeptis Therapeutics Holdi... | Christopher Calise | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 30,000 | 30,000 | - | - | Non-qualified Stock Options (right to buy) |